Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 5/20 | 0.60 |
| ▸ | CA9 | Q16790 | 5/20 | 0.60 |
| ▸ | DAO | P14920 | 2/20 | 0.53 |
| ▸ | DDO | Q99489 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA3 | P07451 | 1/20 | 0.47 |
| ▸ | CA4 | P22748 | 1/20 | 0.47 |
| ▸ | CA6 | P23280 | 1/20 | 0.47 |
| ▸ | CA5A | P35218 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.47 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | NSD2 | O96028 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HCAR1 | Q9BXC0 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30063823 | 1.00 | CA12 (0.60) | CA12CA9DAODDOCYP1A2 | |
| SCHEMBL12569582 | 0.77 | CA12 (0.47) | CA12CA9DAOCA1CA3 | |
| SCHEMBL16050842 | 0.77 | CA12 (0.62) | CA12CA9CYP1A2CA1CA3 | |
| SCHEMBL8919065 | 0.76 | CA12 (0.56) | CA12CA9DAODDOCA1 | |
| SCHEMBL3784446 | 0.75 | CA12 (0.55) | CA12CA9CA1CA3CA4 | |
| SCHEMBL19751458 | 0.75 | CA12 (0.60) | CA12CA9DAODDOCA1 | |
| SCHEMBL29385308 | 0.75 | CA12 (0.60) | CA12CA9DAODDOCYP1A2 | |
| SCHEMBL3137037 | 0.75 | CA12 (1.00) | CA12CA9DAOCA1CA3 | |
| SCHEMBL3224071 | 0.75 | CA12 (0.60) | CA12CA9CYP1A2CA1CA3 | |
| SCHEMBL4178782 | 0.75 | CA12 (1.00) | CA12CA9DAODDOCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 120 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1004205-B | Process for preparing quinolone cardiotonic excitant | 菲泽有限公司 | 1989-05-17 | — | — | CN | claimed |
| CN-86108133-A | CARBOSTYRIL CARDIOTONIC EXCITANT | — | 1987-09-09 | — | — | CN | claimed |
| US-20240343709-A1 | SUBSTITUTED HETEROCYCLES AS ALDEHYDE DEHYDROGENASE INHIBITORS | THE TRUSTEES OF PRINCETON UNIVERSITY | 2024-10-17 | — | — | US | disclosed |
| US-20240327354-A1 | GRAM-NEGATIVE BACTERIA EFFLUX PUMP INHIBITORS | INSTITUT PASTEUR DE LILLE (FR) | 2024-10-03 | — | — | US | disclosed |
| US-12054475-B2 | Substituted heterocycles as aldehyde dehydrogenase inhibitors | KAYOTHERA INC. (US) | 2024-08-06 | — | — | US | disclosed |
| US-20240132469-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | KAYOTHERA INC. (US) | 2024-04-25 | — | — | US | disclosed |
| CN-117897370-A | Heterocyclic compounds and their use | 凯悦施那有限公司 | 2024-04-16 | — | — | CN | disclosed |
| EP-4326696-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Kayothera Inc. (US) | 2024-02-28 | — | — | EP | disclosed |
| US-20230303586-A1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230303586-A1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2023-09-28 | — | — | US | disclosed |
| WO-2023002011-A1 | GRAM-NEGATIVE BACTERIA EFFLUX PUMP INHIBITORS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2023-01-26 | — | — | WO | disclosed |
| US-20050239825-A1 | Modulation of inflammatory and metastatic processes | CHIRON CORPORATION | 2005-10-27 | — | — | US | disclosed |
| US-20050209247-A1 | Lactate salt of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one; improved water solubility and physicochemical properties (e.g., stability, hygroscopicity, crystallinity, and compactibility); vascular endothelial growth factor receptor tyrosine kinase inhibitors | CHIRON CORPORATION | 2005-09-22 | — | — | US | disclosed |
| US-20050154024-A1 | Compounds useful in therapy | PFIZER INC | 2005-07-14 | — | — | US | disclosed |
| EP-0524846-A1 | 2-(Piperidin-1-yl)ethanol derivatives, their preparation and their use in therapeutics | SYNTHELABO (FR) | 1993-01-27 | — | — | EP | disclosed |
| CN-1004205-B | Process for preparing quinolone cardiotonic excitant | 菲泽有限公司 | 1989-05-17 | — | — | CN | disclosed |
| CN-85104392-B | Quinolone inotropic agents | 辉瑞公司 | 1988-02-17 | — | — | CN | disclosed |
| CN-86108133-A | CARBOSTYRIL CARDIOTONIC EXCITANT | — | 1987-09-09 | — | — | CN | disclosed |
| CN-85104392-A | The preparation method of quinolone inotropic agents | — | 1986-12-24 | — | — | CN | disclosed |
| US-3956420-A | CPOLYOLEFIN COMPOSITION FOR ELECTRICAL INSULATIONFERROCENE, 8-SUBSTITUTED QUINOLINE | DAINICHI-NIPPON CABLES, LTD. (JA) | 1976-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240343709-A1 | SUBSTITUTED HETEROCYCLES AS ALDEHYDE DEHYDROGENASE INHIBITORS | ALDH3A1, ALDH2, ALDH1A2 | CA12 1645/4885CA9 579/4885DAO 782/4885 |
| US-12054475-B2 | Substituted heterocycles as aldehyde dehydrogenase inhibitors | ALDH3A1, ALDH2, ALDH1A2 | CA12 1645/4885CA9 579/4885DAO 782/4885 |
| US-20240327354-A1 | GRAM-NEGATIVE BACTERIA EFFLUX PUMP INHIBITORS | ABCB11, ABCB1, ATP4B | CA12 4622/4885CA9 2996/4885DAO 2240/4885 |
| US-20240132469-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | CYP11B2, ALDH2, PDK1 | CA12 1172/4885CA9 475/4885DAO 1343/4885 |
| US-20050239825-A1 | Modulation of inflammatory and metastatic processes | VCAM1, EPCAM, ICAM1 | CA12 268/4885CA9 777/4885DAO 3484/4885 |
| US-20050154024-A1 | Compounds useful in therapy | PTGER4, PTGER3, ALOX5 | CA12 4124/4885CA9 3747/4885DAO 2672/4885 |
| US-20230303586-A1 | INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | CA12 3651/4885CA9 1880/4885DAO 3260/4885 |
| US-20050209247-A1 | Lactate salt of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one; improved water solubility and physicochemical properties (e.g., stability, hygroscopicity, crystallinity, and compactibility); vascular endothelial growth factor receptor tyrosine kinase inhibitors | KDR, FLT4, FLT1 | CA12 166/4885CA9 149/4885DAO 1470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.